News
GDRX
6.97
+4.65%
0.31
GoodRx Holdings Insider Ups Holding During Year
GoodRx Holdings, Inc.'s (NASDAQ:GDRX) insiders have been buying shares in the last year. The biggest single purchase by an insider was by Scott Wagner for US$677k. GoodRx Holding insiders own about 3.1% of the company. Over the last 12 months, Goodrx Holdings insiders have bought more shares than they sold. You can see the insider transactions of GoodRX Holdings over the years.
Simply Wall St · 12h ago
GDRX Alert: Rosen, Skilled Investor Counsel, Encourages GoodRx Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – GDRX
Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of common stock of GoodRx Holdings, Inc. Between September 23, 2020 and November 8, 2022. If you purchased GoodRX common stock during the Class Period, you may be entitled to compensation. A class action has already been filed. To join the goodRx class action, you must move the court by June 21, 2024.
Barchart · 22h ago
GDRX INVESTOR ALERT: Kessler Topaz Meltzer & Check, LLP Files A Securities Fraud Class Action Lawsuit Against GoodRX Holdings, Inc. And Encourages Investors With Losses To Contact The Firm
Kessler Topaz Meltzer & Check, LLP has filed a securities fraud class action lawsuit against GoodRx Holdings, Inc. The lawsuit was filed on behalf of investors who purchased or acquired goodrx common stock between September 23, 2020, and November 8, 2022. Goodrx operates a price comparison platform for prescription drugs. The price of good rx stock plummeted 25% on May 9, 2022, when the company revealed Kroger could unilaterally refuse to accept its discounts.
Barchart · 1d ago
Weekly Report: what happened at GDRX last week (0415-0419)?
Weekly Report · 1d ago
Weekly Report: what happened at GDRX last week (0408-0412)?
Weekly Report · 04/15 09:25
Analysts Are Bullish on These Healthcare Stocks: GoodRx Holdings (GDRX), Arcutis Biotherapeutics (ARQT)
TipRanks · 04/12 10:40
R1 RCM, Health Catalyst downgraded as KeyBanc reviews health-tech space
R1 RCM, Health Catalyst downgraded as KeyBanc Capital Markets downgrades the stocks ahead of Q1 earnings. The firm upgraded GoodRx Holdings and Certara ahead of the healthcare IT space. The analyst cited the recent cybersecurity incident at UnitedHealth's Change Healthcare unit.
Seeking Alpha · 04/10 16:56
GoodRx Holdings Analyst Turns Bullish Ahead Of Q1 Earnings
GoodRx Holdings Inc (NASDAQ:GDRX) got an upgrade last month from Wells Fargo analyst. The stock was trading at a discount to its peers and its historical average, KeyBanc Capital Markets says. GoodRx's app downloads have been "encouraging," the analyst says.
Benzinga · 04/10 16:10
GOODRX HOLDINGS INC <GDRX.O>: KEYBANC RAISES OVERWEIGHT FROM SECTOR WEIGHT
Reuters · 04/10 10:10
GoodRx Holdings Raised to Overweight From Sector Weight by Keybanc
Dow Jones · 04/10 08:50
GoodRx Holdings Price Target Announced at $9.00/Share by Keybanc
Dow Jones · 04/10 08:50
Keybanc Upgrades GoodRx Holdings to Overweight, Announces $9 Price Target
Benzinga · 04/10 08:40
Weekly Report: what happened at GDRX last week (0401-0405)?
Weekly Report · 04/08 09:27
GoodRx Holdings files to sell 99.98M shares for holders
GoodRx Holdings files to sell 99.98M shares for holders Apr. 05, 2024 5:28 PM ET. GoodRx holdings, Inc. Filed a prospectus related to the proposed resale of about 99. 98M shares by selling stockholders.
Seeking Alpha · 04/05 21:28
GOODRX HOLDINGS INC: SELLING SECURITYHOLDERS MAY OFFER UP TO 99.98 MLN SHARES OF CLASS A COMMON STOCK FROM TIME TO TIME IN ONE OR MORE OFFERINGS
Reuters · 04/05 21:05
‘Time to Hit Buy,’ Says Wells Fargo About These 2 Stocks
Wells Fargo analysts have upgraded their ratings on two names they see as 'Buy' stocks. GoodRx Holdings and NeuroPace are two of the names the analysts at the financial giant have turned bullish on. Both stocks have double-digit upsides and are expected to rise in the coming year. Goodrx is an online pharmacy that streamlines the distribution of prescription medications. NeuroPACE is a company in the medical field of epilepsy.
TipRanks · 04/04 13:20
Analysts Have Conflicting Sentiments on These Healthcare Companies: Biomea Fusion (BMEA) and GoodRx Holdings (GDRX)
TipRanks · 04/02 11:30
Weekly Report: what happened at GDRX last week (0325-0329)?
Weekly Report · 04/01 09:27
While institutions invested in GoodRx Holdings, Inc. (NASDAQ:GDRX) benefited from last week's 3.1% gain, private equity firms stood to gain the most
Top 2 shareholders of GoodRx Holdings, Inc. (NASDAQ:GDRX) own 51% of the company. With a 58% stake, private equity firms possess the maximum shares in GoodRX Holdings. Institutions own 14% of Goodrx Holdings. The company has a significant amount of ownership in the company, and is owned by a number of institutions. Good rx Holdings's ownership of 58% suggests the company's owners are influenced by the larger public. It is important to understand the ownership structure of a company to understand its future growth.
Simply Wall St · 03/28 12:12
Why GoodRx Surged Today
Wells Fargo raised its rating on GoodRX from "equal weight" to "overweight" GoodRx is a prescription drug price-comparison site and telehealth platform. The company beat expectations in its fourth-quarter report. The stock is up 7.5% today and up 28% since January.
The Motley Fool · 03/25 20:24
More
Webull provides a variety of real-time GDRX stock news. You can receive the latest news about Goodrx Holdings, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About GDRX
GoodRx Holdings, Inc. provides a consumer-focused digital healthcare platform in the United States. It offer consumers free access to transparent and lower prices for generic and brand medications, as well as comprehensive healthcare research and information. It also equips healthcare professionals to find and prescribe affordable medications. It offers information and tools to help consumers compare prices and save on their prescription drug purchases. It operates a price comparison platform that provides consumers with geographically relevant prescription pricing and provides access to negotiated prices through its codes that can be used to save money on prescriptions across the United States (the prescription transactions offering). It also offers other healthcare products and services, including pharmaceutical manufacturer solutions, subscriptions, and telehealth services. Its subscription offerings provide additional benefits to consumers of its prescription transactions offering.